Literature DB >> 20172739

The role of invariant NKT cells at the interface of innate and adaptive immunity.

Vincenzo Cerundolo, Mitch Kronenberg.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20172739     DOI: 10.1016/j.smim.2010.01.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


× No keyword cloud information.
  14 in total

1.  Critical roles of RasGRP1 for invariant NKT cell development.

Authors:  Shudan Shen; Yong Chen; Balachandra K Gorentla; Jianxin Lu; James C Stone; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

2.  The differential roles of mTOR, ERK, and JNK pathways in invariant natural killer T-cell function and survival.

Authors:  Jun Tian; Li Liu; Xiangai Wang; Xuewu Sun; Suli Mu; Chuanjun Wu; Maoqiang Han
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

3.  iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions.

Authors:  Jinhong Wu; Jialong Yang; Kai Yang; Hongxia Wang; Balachandra Gorentla; Jinwook Shin; Yurong Qiu; Loretta G Que; W Michael Foster; Zhenwei Xia; Hongbo Chi; Xiao-Ping Zhong
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

Review 4.  Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia.

Authors:  Vanessa H Brait; Thiruma V Arumugam; Grant R Drummond; Christopher G Sobey
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-01       Impact factor: 6.200

5.  Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function.

Authors:  Jinwook Shin; Shang Wang; Wenhai Deng; Jinhong Wu; Jimin Gao; Xiao-Ping Zhong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

6.  Development of a qPCR method to rapidly assess the function of NKT cells.

Authors:  Silke Sohn; Irina Tiper; Emily Japp; Wenji Sun; Katherine Tkaczuk; Tonya J Webb
Journal:  J Immunol Methods       Date:  2014-04-12       Impact factor: 2.303

7.  Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.

Authors:  Joshua Richter; Natalia Neparidze; Lin Zhang; Shiny Nair; Tamara Monesmith; Ranjini Sundaram; Fred Miesowicz; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2012-10-24       Impact factor: 22.113

8.  Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.

Authors:  Jinhong Wu; Jinwook Shin; Danli Xie; Hongxia Wang; Jimin Gao; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

9.  Development of genetically engineered iNKT cells expressing TCRs specific for the M. tuberculosis 38-kDa antigen.

Authors:  Zhen-Min Jiang; Wei Luo; Qian Wen; Su-Dong Liu; Pei-Pei Hao; Chao-Ying Zhou; Ming-Qian Zhou; Li Ma
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

10.  Diacylglycerol kinase zeta positively controls the development of iNKT-17 cells.

Authors:  Jinhong Wu; Shudan Shen; Jialong Yang; Zhenwei Xia; Xiao-Ping Zhong
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.